Logo image of STOK

STOKE THERAPEUTICS INC (STOK) Stock Fundamental Analysis

USA - NASDAQ:STOK - US86150R1077 - Common Stock

34.68 USD
+0.03 (+0.09%)
Last: 10/21/2025, 8:00:00 PM
34.99 USD
+0.31 (+0.89%)
After Hours: 10/21/2025, 8:00:00 PM
Fundamental Rating

5

Overall STOK gets a fundamental rating of 5 out of 10. We evaluated STOK against 534 industry peers in the Biotechnology industry. STOK has an excellent financial health rating, but there are some minor concerns on its profitability. STOK is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

STOK had positive earnings in the past year.
In the past year STOK had a positive cash flow from operations.
In the past 5 years STOK always reported negative net income.
In the past 5 years STOK always reported negative operating cash flow.
STOK Yearly Net Income VS EBIT VS OCF VS FCFSTOK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With an excellent Return On Assets value of 13.65%, STOK belongs to the best of the industry, outperforming 95.13% of the companies in the same industry.
The Return On Equity of STOK (15.67%) is better than 94.76% of its industry peers.
STOK has a Return On Invested Capital of 9.20%. This is amongst the best in the industry. STOK outperforms 93.82% of its industry peers.
Industry RankSector Rank
ROA 13.65%
ROE 15.67%
ROIC 9.2%
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
STOK Yearly ROA, ROE, ROICSTOK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

STOK has a better Profit Margin (26.26%) than 95.88% of its industry peers.
STOK has a better Operating Margin (20.15%) than 94.57% of its industry peers.
Industry RankSector Rank
OM 20.15%
PM (TTM) 26.26%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STOK Yearly Profit, Operating, Gross MarginsSTOK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

8

2. Health

2.1 Basic Checks

STOK has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for STOK has been increased compared to 1 year ago.
STOK has more shares outstanding than it did 5 years ago.
There is no outstanding debt for STOK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
STOK Yearly Shares OutstandingSTOK Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
STOK Yearly Total Debt VS Total AssetsSTOK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

STOK has an Altman-Z score of 23.13. This indicates that STOK is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 23.13, STOK belongs to the top of the industry, outperforming 91.20% of the companies in the same industry.
There is no outstanding debt for STOK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 23.13
ROIC/WACC0.98
WACC9.35%
STOK Yearly LT Debt VS Equity VS FCFSTOK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 6.98 indicates that STOK has no problem at all paying its short term obligations.
STOK has a better Current ratio (6.98) than 69.10% of its industry peers.
STOK has a Quick Ratio of 6.98. This indicates that STOK is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.98, STOK is doing good in the industry, outperforming 69.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.98
Quick Ratio 6.98
STOK Yearly Current Assets VS Current LiabilitesSTOK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 142.58% over the past year.
Looking at the last year, STOK shows a very strong growth in Revenue. The Revenue has grown by 1218.65%.
EPS 1Y (TTM)142.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.04%
Revenue 1Y (TTM)1218.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%186.01%

3.2 Future

Based on estimates for the next years, STOK will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.02% on average per year.
STOK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 68.28% yearly.
EPS Next Y117.64%
EPS Next 2Y-30.95%
EPS Next 3Y-16.56%
EPS Next 5Y16.02%
Revenue Next Year914.78%
Revenue Next 2Y31.67%
Revenue Next 3Y35.53%
Revenue Next 5Y68.28%

3.3 Evolution

STOK Yearly Revenue VS EstimatesSTOK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
STOK Yearly EPS VS EstimatesSTOK Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

STOK is valuated quite expensively with a Price/Earnings ratio of 37.29.
Based on the Price/Earnings ratio, STOK is valued cheaply inside the industry as 92.88% of the companies are valued more expensively.
STOK is valuated rather expensively when we compare the Price/Earnings ratio to 27.77, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for STOK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 37.29
Fwd PE N/A
STOK Price Earnings VS Forward Price EarningsSTOK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

STOK's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. STOK is cheaper than 92.13% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, STOK is valued cheaper than 93.82% of the companies in the same industry.
Industry RankSector Rank
P/FCF 31.08
EV/EBITDA 35.64
STOK Per share dataSTOK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A cheap valuation may be justified as STOK's earnings are expected to decrease with -16.56% in the coming years.
PEG (NY)0.32
PEG (5Y)N/A
EPS Next 2Y-30.95%
EPS Next 3Y-16.56%

More info and screens

0

5. Dividend

5.1 Amount

STOK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STOKE THERAPEUTICS INC

NASDAQ:STOK (10/21/2025, 8:00:00 PM)

After market: 34.99 +0.31 (+0.89%)

34.68

+0.03 (+0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-11 2025-11-11
Inst Owners118.79%
Inst Owner Change0.51%
Ins Owners4.3%
Ins Owner Change-28.1%
Market Cap1.90B
Analysts84.71
Price Target24.71 (-28.75%)
Short Float %21.75%
Short Ratio11.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)291.04%
Min EPS beat(2)23.41%
Max EPS beat(2)558.67%
EPS beat(4)4
Avg EPS beat(4)165.54%
Min EPS beat(4)13.51%
Max EPS beat(4)558.67%
EPS beat(8)8
Avg EPS beat(8)88.85%
EPS beat(12)11
Avg EPS beat(12)62.04%
EPS beat(16)12
Avg EPS beat(16)29.4%
Revenue beat(2)2
Avg Revenue beat(2)863.06%
Min Revenue beat(2)52.02%
Max Revenue beat(2)1674.1%
Revenue beat(4)4
Avg Revenue beat(4)546.83%
Min Revenue beat(4)43.23%
Max Revenue beat(4)1674.1%
Revenue beat(8)7
Avg Revenue beat(8)280.95%
Revenue beat(12)10
Avg Revenue beat(12)183.53%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)8.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.04%
EPS NY rev (1m)0%
EPS NY rev (3m)384.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-29.68%
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.87%
Valuation
Industry RankSector Rank
PE 37.29
Fwd PE N/A
P/S 9.51
P/FCF 31.08
P/OCF 30.85
P/B 5.67
P/tB 5.67
EV/EBITDA 35.64
EPS(TTM)0.93
EY2.68%
EPS(NY)-2.88
Fwd EYN/A
FCF(TTM)1.12
FCFY3.22%
OCF(TTM)1.12
OCFY3.24%
SpS3.65
BVpS6.11
TBVpS6.11
PEG (NY)0.32
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 13.65%
ROE 15.67%
ROCE 11.65%
ROIC 9.2%
ROICexc 32.43%
ROICexgc 32.43%
OM 20.15%
PM (TTM) 26.26%
GM N/A
FCFM 30.59%
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 22.67%
Cap/Sales 0.23%
Interest Coverage 250
Cash Conversion 145.71%
Profit Quality 116.5%
Current Ratio 6.98
Quick Ratio 6.98
Altman-Z 23.13
F-Score8
WACC9.35%
ROIC/WACC0.98
Cap/Depr(3y)110.09%
Cap/Depr(5y)114.39%
Cap/Sales(3y)16.96%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)142.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.04%
EPS Next Y117.64%
EPS Next 2Y-30.95%
EPS Next 3Y-16.56%
EPS Next 5Y16.02%
Revenue 1Y (TTM)1218.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%186.01%
Revenue Next Year914.78%
Revenue Next 2Y31.67%
Revenue Next 3Y35.53%
Revenue Next 5Y68.28%
EBIT growth 1Y135.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year110.74%
EBIT Next 3Y-11.06%
EBIT Next 5Y21.61%
FCF growth 1Y167.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y170.32%
OCF growth 3YN/A
OCF growth 5YN/A